Showing 3991-4000 of 7132 results for "".
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Mount Sinai Physician Promises $5 Million Bequest to Support the Kimberly and Eric J. Waldman Department of Dermatologyhttps://practicaldermatology.com/news/mount-sinai-physician-promises-5-million-bequest-to-support-the-kimberly-and-eric-j-waldman-department-of-dermatology/2461536/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai received a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology. This gift represents Dr. Edelson’s commitment to advancing dermatolo
- Merz Aesthetics, NWSL’s North Carolina Courage Expand Partnershiphttps://practicaldermatology.com/news/merz-aesthetics-partners-with-wsls-north-carolina-courage-to-fuel-confidence-on-and-off-field/2461532/Merz Aesthetics is expanding its sponsorship of the North Carolina Courage, two-time champions of the National Women’s Soccer League (NWSL). “This partnership is so meaningful for us at Merz Aesthetics,” says Patrick Urban, North America President, in
- CDC Report: Seven Percent of Adults and 11 Percent of Kids Had Eczema in 2021https://practicaldermatology.com/news/cdc-report-seven-percent-of-adults-and-11-percent-of-kids-had-eczema-in-2021/2461530/Slightly more than 7% of adults and nearly 11% of kids had eczema in 2021, according to two new reports in the CDC’s National Center for Health Statistics Data Brief. W
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Elsevier Introduces First 3D Human Anatomy Model in Different Skin Toneshttps://practicaldermatology.com/news/elsevier-introduces-first-3d-human-anatomy-model-in-different-skin-tones/2461516/Elsevier is rolling out the newest edition of its 3D anatomy teaching platform, Complete Anatomy 2023, which will feature the most expansive set of skin tone selections ever available in global health education.
- Phase 2b Study: Arcutis' Roflumilast Cream Shows Sustained Efficacy in Adults with Chronic Plaque Psoriasishttps://practicaldermatology.com/news/pgase-2b-study-arcutis-roflumilast-cream-shows-sustained-efficacy-in-adults-with-chronic-plaque-psoriasis/2461513/Arcutis' roflumilast cream showed sustained efficacy with clearance for median of 10 Months in adults with chronic plaque psoriasis, according to an open label Phase 2 long-term safety study presented at the Winter Clinical dermatology meeting. Roflumilast cream
- Twenty New Products Earn NPF Seal of Recognitionhttps://practicaldermatology.com/news/twenty-new-products-earn-npf-seal-of-recognition/2461512/Twenty new products have earned the National Psoriasis Foundation’s Seal of Recognition. Each of these 20 products passed the same rigorous application, review, and approval process as the other 45 products that comprise the
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced